Your search for non small cell lung cancer returned 274 results

Cancer patients with biomarker-positive tumors have better outcomes on immune checkpoint inhibitor therapy, a meta-analysis suggests.

A regulatory decision is expected on November 27, 2023.

Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody.

The designation is supported by data from the ongoing phase 2 KEYNOTE-942 study, which included 157 patients with stage III/IV melanoma following complete resection.

The approval was based on data from the KEYNOTE-091 trial.

The ready-to-dilute formulation was developed to eliminate the reconstitution step with Alimta.

Krazati is a highly selective and potent oral small molecule inhibitor of KRASG12C.

According to the CRL, the application could not be approved in its present form as additional data, including a randomized controlled trial, would be required.

The approval was based on data from a phase 3 POSEIDON study.

Findings showed that treatment with cemiplimab-rwlc plus platinum-based chemotherapy demonstrated a statistically significant improvement in overall survival.